Valneva Submits Label Extension Applications for Chikungunya Vaccine IXCHIQ® to EMA and Health Canada
Tuesday, 17 September 2024, 22:12
Overview of IXCHIQ®
Chikungunya vaccine IXCHIQ® was developed by Valneva, a company focused on specialty vaccines. It aims to protect individuals from the chikungunya virus, which can lead to debilitating symptoms.
Recent Developments
- Valneva announced the submission of label extension applications.
- Applications made to both the European Medicines Agency (EMA) and Health Canada.
- Expansion of IXCHIQ® usage is a crucial step in public health initiatives.
The Importance of Vaccination
Vaccination is a fundamental aspect of preventing infectious diseases, particularly as cases of chikungunya continue to increase globally.
For further in-depth details about this significant step in vaccine progress, please visit the source of this news.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.